Compare TRNR & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | NUWE |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | 72 | 38 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.2M |
| IPO Year | 2023 | N/A |
| Metric | TRNR | NUWE |
|---|---|---|
| Price | $4.37 | $3.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 3.9M |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | N/A |
| Revenue This Year | $264.92 | $11.14 |
| Revenue Next Year | N/A | $18.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $0.19 | $0.08 |
| 52 Week High | $8.20 | $25.95 |
| Indicator | TRNR | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 85.40 | 82.99 |
| Support Level | $0.93 | $2.87 |
| Resistance Level | N/A | $3.93 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | 0.46 | 0.38 |
| Stochastic Oscillator | 90.14 | 81.17 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.